Cellectar Biosciences (CLRB) EBT Growth (1y) (2011 - 2026)
Cellectar Biosciences (CLRB) EBT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.48% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.60% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 88.57% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.23% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 213.87% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 530.43% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -182.24% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 96.45% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -12.04% |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.03% |
| Dec 31, 2025 | 95.14% |
| Sep 30, 2025 | 64.29% |
| Jun 30, 2025 | 54.12% |
| Mar 31, 2025 | 48.64% |
| Dec 31, 2024 | -744.87% |
| Sep 30, 2024 | -45.01% |
| Jun 30, 2024 | -68.43% |
| Mar 31, 2024 | -44.22% |
| Dec 31, 2023 | 82.29% |
| Sep 30, 2023 | -20.40% |
| Jun 30, 2023 | -15.24% |
| Mar 31, 2023 | -44.17% |
| Dec 31, 2022 | -1,205.38% |
| Sep 30, 2022 | -29.70% |
| Jun 30, 2022 | -15.46% |
| Mar 31, 2022 | 5.28% |
| Dec 31, 2021 | -61.99% |
| Sep 30, 2021 | -52.09% |
| Jun 30, 2021 | -70.35% |